Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
McKesson
Merck
Harvard Business School
Mallinckrodt

Last Updated: January 22, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Buparlisib

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Buparlisib?

Buparlisib is an investigational drug.

There have been 32 clinical trials for Buparlisib. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2011.

The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Breast Neoplasms. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and National Cancer Institute (NCI).

There are sixty-five US patents protecting this investigational drug and seven hundred and fifty-one international patents.

Recent Clinical Trials for Buparlisib
TitleSponsorPhase
A Clinical Trial of Buparlisib and Ibrutinib in LymphomaJanssen Scientific Affairs, LLCPhase 1
A Clinical Trial of Buparlisib and Ibrutinib in LymphomaNovartis PharmaceuticalsPhase 1
A Clinical Trial of Buparlisib and Ibrutinib in LymphomaMemorial Sloan Kettering Cancer CenterPhase 1

See all Buparlisib clinical trials

Clinical Trial Summary for Buparlisib

Top disease conditions for Buparlisib
Top clinical trial sponsors for Buparlisib

See all Buparlisib clinical trials

US Patents for Buparlisib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Buparlisib   Start Trial Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity The University of North Carolina at Chapel Hill (Chapel Hill, NC)   Start Trial
Buparlisib   Start Trial Antibody drug conjugates Novartis AG (Basel, CH)   Start Trial
Buparlisib   Start Trial Combination therapy comprising a CDK4/6 inhibitor and a PI3K inhibitor for use in the treatment of cancer Novartis AG (Basel, CH)   Start Trial
Buparlisib   Start Trial Compounds and compositions as inhibitors of MEK Novartis AG (Basel, CH)   Start Trial
Buparlisib   Start Trial Pharmaceutical combinations   Start Trial
Buparlisib   Start Trial Manufacturing process for triazine, pyrimidine and pyridine derivatives UNIVERSITAET BASEL (Basel, CH) PIQUR THERAPEUTICS AG (Basel, CH)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Buparlisib

Drugname Country Document Number Estimated Expiration Related US Patent
Buparlisib Australia 2015244171 2034-04-11   Start Trial
Buparlisib Australia 2015244179 2034-04-11   Start Trial
Buparlisib Canada 2945128 2034-04-11   Start Trial
Buparlisib Canada 2945129 2034-04-11   Start Trial
Buparlisib China 106414451 2034-04-11   Start Trial
Buparlisib China 106459063 2034-04-11   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Medtronic
Colorcon
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.